You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Microfluidic High-throughput Platform for Determining of Kinetic Constants of Enzyme Variants

    SBC: CFD Research Corporation            Topic: CBD10107

    Molecular biology techniques allow generating combinatorial libraries of large number of enzyme variants. However, there is currently no technology available for screening the enzyme libraries for identifying variants with improved activity for the substrate. We propose to develop a novel, microfluidic, high-throughput platform for determining kinetic constants of enzyme variants and identifying v ...

    SBIR Phase I 2010 Department of DefenseOffice for Chemical and Biological Defense
  2. A Novel Microfludic Device for Drug Toxicity Studies

    SBC: CFD Research Corporation            Topic: CBD10103

    Current drug discovery and development programs are severely limited by the expensive animal trials and oversimplified in vitro models. Results obtained from the in vitro models are not predictive of in vivo toxicity owing to significant difference in testing from the in vivo physiological conditions. In this context, we propose to develop and demonstrate a novel microfluidic device for quantitati ...

    SBIR Phase I 2010 Department of DefenseOffice for Chemical and Biological Defense
  3. In vitro Models Suitable for High-throughput Screening of Drug Toxicities in Human Tissues

    SBC: Nico Technologies Corp.            Topic: CBD10103

    The drug R&D cycle is long and very expensive. In many ways, this status quo can no longer be sustained. One of the reasons for such great cost is that the vast majority of drug candidates are screened out at the stages of animal and human trials. More efficient methods of testing of drugs at the stage of ex-vivo studies, which are substantially less expensive than animal and human testing cyc ...

    SBIR Phase I 2010 Department of DefenseOffice for Chemical and Biological Defense
  4. AC Impedance Sensor for Collective Protection Filter Residual Life Indicator

    SBC: Guild Associates, Inc.            Topic: CBD10106

    Guild Associates, Inc. proposes to develop and evaluate an active electrochemical sensor based residual life indicator (RLI) for adsorptive carbon filters. The sensing system of the RLI will operate by analyzing the electrochemical state of the carbon within the filter and evaluate the remaining adsorptive reactive capacities of the filter. The sensor design will be challenged against an array of ...

    SBIR Phase I 2010 Department of DefenseOffice for Chemical and Biological Defense
  5. Prototype Application of Mobile, Cloud-based, Watson-Like Technologies for TBI/PTSD Clinical Decision Support and Predictive Analytics

    SBC: Lifecom Inc.            Topic: DHP12005

    The goal of this Phase I project is to develop an engineering plan and to create a prototype for a mobile, cloud-based expert system to aid in diagnosis, decision support and predictive analytics to improve clinical outcomes for veterans, soldiers, and their families with traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD). Lifecom, Inc. is a health information technology compan ...

    SBIR Phase I 2013 Department of DefenseDefense Health Agency
  6. An automated, high throughput, resin-free device for large scale protein purification

    SBC: CFD Research Corporation            Topic: CBD12102

    Protein manufacturing is of paramount importance to chemical and biological defense applications. High-throughput protein purification is a critical need for rapidly scaling the target protein product. Existing purification methods primarly rely on synthetic-resin based chromatography, which is time-consuming, labor-intensive, expensive, and consequently, ill-suited for developing rapid countermea ...

    SBIR Phase I 2013 Department of DefenseOffice for Chemical and Biological Defense
  7. Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels

    SBC: Washburn Therapeutics, Inc.            Topic: DHP12016

    Washburn Therapeutics Inc. is developing biologically active gels that control inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company from Carnegie Mellon University. Preliminary results demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosi ...

    SBIR Phase I 2013 Department of DefenseDefense Health Agency
  8. Rapid Sample Transport in Austere Environments

    SBC: Piasecki Aircraft Corporation            Topic: CBD12108

    Piasecki Aircraft proposes to meet the challenge of delivering a biological or chemical sample maintained at less than -20 deg Celcius over a range of up to 1000 miles with a precision landing with a portable unmanned aerial system capable of a vertical takeoff, cruise flight range typical of a fixed wing platform, and able to perform a precision landing. The system consists of a lifting quadrotor ...

    SBIR Phase I 2013 Department of DefenseOffice for Chemical and Biological Defense
  9. Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.

    SBC: Qrono, Inc.            Topic: CBD13107

    Elevated levels of human butyrylcholinesterase (BuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protection is the ability to maintain elevated concentrations of BuChE in the plasma for days or weeks. Thus far, plasma-derived and PEGylated recombinant forms of BuChE have been tested in humans. However, ...

    SBIR Phase I 2013 Department of DefenseOffice for Chemical and Biological Defense
  10. Ear Protection Validation System

    SBC: Benson Medical Instruments Company            Topic: DHP12009

    This proposal contains the description for a hearing protection device (HPD) fit-test instrument, the CCA-200fit. The CCA-200fit has the capability to determine if an individual is receiving effective noise protection from an HPD. The CCA-200fit also has training capabilities via a display, audio, and a touchscreen which will allow it to provide instruction, feedback, and results to the individual ...

    SBIR Phase I 2013 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government